Preserving Performance Status and the Impact of NALIRIFOX's NCCN Inclusion on Clinical Practice

Maintaining patient functionality throughout long-term chemotherapy is one of the most critical and challenging goals in mPDAC management. This segment outlines proactive toxicity management strategies, including prophylactic antiemetics, dual anti-diarrheal prescriptions, and a low threshold for oxaliplatin dose reduction or discontinuation upon grade 2 neuropathy. The discussion then addresses NALIRIFOX's inclusion in NCCN guidelines as a Category 2A first-line option alongside FOLFIRINOX and gemcitabine/nab-paclitaxel. While the designation reflects strong clinical evidence, the absence of direct head-to-head data means no regimen holds a Category 1 recommendation, reinforcing that treatment selection remains a patient-by-patient decision. Both physicians report no significant reimbursement challenges following FDA approval, attributing this to the robust phase III evidence base supporting NALIRIFOX in the frontline setting.